There have been previous reports that BRAF (V600E) mutation stimulates migration and invasion of thyroid cancer cells, through the increased expression of EMT-related markers via a MEK/ERK-dependent mechanism and that these processes together with tumor proliferation can be inhibited by BRAF inhibitor PLX4720 treatment [40, 41]. The gene discussed is MAP2K7; the disease is thyroid cancer.